Aliases & Classifications for Hypoxia

MalaCards integrated aliases for Hypoxia:

Name: Hypoxia 53 17 71

External Ids:

UMLS 71 C0242184

Summaries for Hypoxia

Novus Biologicals : 55 Hypoxia is a pathological condition in which the body as a whole (generalized hypoxia) or region of the body (tissue hypoxia) is deprived of adequate oxygen supply. Hypoxia contributes significantly to the pathophysiology of major categories of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease. Hypoxia inducible factor-1 (HIF-1) is a transcription factor that regulates adaptive responses to a lack of oxygen in mammalian cells. HIF-1 consists of two proteins, HIF-1 alpha and HIF-1 beta. HIF-1 alpha accumulates under hypoxic conditions whereas HIF-1 beta is constitutively expressed. HIF-1 alpha is an important mediator of the hypoxic response of tumor cells and controls the up-regulation of a number of factors important for solid tumor expansion including the angiogenic factor VEGF.

MalaCards based summary : Hypoxia is related to chronic mountain sickness and renal cell carcinoma, nonpapillary, and has symptoms including seizures, fever and dyspnea. An important gene associated with Hypoxia is KMT2A (Lysine Methyltransferase 2A), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Pathways in cancer. The drugs Metformin and Zinc have been mentioned in the context of this disorder. Affiliated tissues include brain, lung and endothelial, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Hypoxia is a condition in which the body or a region of the body is deprived of adequate oxygen supply... more...

Related Diseases for Hypoxia

Diseases related to Hypoxia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1422)
# Related Disease Score Top Affiliating Genes
1 chronic mountain sickness 32.4 PDK1 EGLN3
2 renal cell carcinoma, nonpapillary 32.0 VHL MTOR HIF1AN HIF1A EPAS1 EGLN3
3 acute mountain sickness 31.4 VHL HIF1AN HIF1A EGLN1
4 polycythemia 31.2 VHL HIF1A EPAS1 EGLN1
5 pheochromocytoma 30.8 VHL HIF1A EPAS1 EGLN3 EGLN2 EGLN1
6 paraganglioma 30.6 VHL HIF1A EPAS1 EGLN1
7 clear cell renal cell carcinoma 30.5 VHL MTOR HIF1A EPAS1 EP300 EGLN3
8 hemangioblastoma 30.5 VHL HIF1A EPAS1
9 kidney cancer 30.5 VHL PDK1 MTOR HIF1A EPAS1
10 fumarate hydratase deficiency 30.1 VHL HIF1A
11 erythrocytosis, familial, 2 30.0 VHL HIF1A EPAS1 EGLN3 EGLN2 EGLN1
12 acquired polycythemia 29.9 EPAS1 EGLN1
13 retinal hemangioblastoma 29.8 VHL HIF1A EPAS1
14 cerebral hypoxia 12.7
15 pulmonary hypertension owing to lung disease and/or hypoxia 12.4
16 respiratory underresponsiveness to hypoxia and hypercapnia 12.3
17 polycythemia due to hypoxia 12.2
18 anoxia 11.9
19 neonatal hypoxic and ischemic brain injury 11.8
20 asphyxia neonatorum 11.7
21 exudative vitreoretinopathy 1 11.6
22 pulmonary edema 11.5
23 apnea of prematurity 11.4
24 methemoglobinemia 11.4
25 severe acute respiratory syndrome 11.4
26 hantavirus pulmonary syndrome 11.4
27 congenital extrahepatic portosystemic shunt 11.4
28 tempi syndrome 11.4
29 methemoglobinemia due to deficiency of methemoglobin reductase 11.2
30 pneumothorax, primary spontaneous 11.1
31 methemoglobinemia and ambiguous genitalia 11.1
32 exudative vitreoretinopathy 2, x-linked 11.1
33 exudative vitreoretinopathy 4 11.1
34 exudative vitreoretinopathy 5 11.1
35 exudative vitreoretinopathy 6 11.1
36 exudative vitreoretinopathy 7 11.1
37 leukostasis 11.1
38 congenital laryngeal palsy 11.1
39 typical congenital nemaline myopathy 11.1
40 pulmonary hypertension 11.0
41 lung cancer susceptibility 3 11.0
42 sleep apnea 10.9
43 ischemia 10.9
44 polycystic kidney disease 10.8
45 glioblastoma multiforme 10.7
46 glioma 10.7
47 glial tumor 10.7
48 pulmonary hypertension, primary, 1 10.6
49 pre-eclampsia 10.6
50 brain injury 10.6

Graphical network of the top 20 diseases related to Hypoxia:



Diseases related to Hypoxia

Symptoms & Phenotypes for Hypoxia

UMLS symptoms related to Hypoxia:


seizures, fever, dyspnea, edema, cachexia, apnea, vertigo, hemoptysis, headache, syncope, cyanosis, chills, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes, cheyne-stokes respiration, coughing, hoarseness, increased sweating, anoxemia, signs and symptoms, respiratory, sneezing, hyperoxia, motor symptom, skin symptoms, physical symptom, physical appearance, body

GenomeRNAi Phenotypes related to Hypoxia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 9.6 HIPK2
2 Decreased viability GR00221-A-1 9.6 PDK1 VHL
3 Decreased viability GR00221-A-2 9.6 EGLN3 EP300 HIPK2 PDK1 VHL
4 Decreased viability GR00221-A-3 9.6 PDK1
5 Decreased viability GR00301-A 9.6 EGLN3 HIPK2 VHL
6 Decreased viability GR00342-S-3 9.6 HIPK2
7 Decreased viability GR00381-A-1 9.6 EGLN3
8 Decreased viability GR00402-S-2 9.6 EGLN3 EP300 HIPK2 PDK1 VHL

MGI Mouse Phenotypes related to Hypoxia:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
2 homeostasis/metabolism MP:0005376 10.4 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
3 cellular MP:0005384 10.37 ARNT EGLN1 EGLN2 EGLN3 EP300 HIF1A
4 growth/size/body region MP:0005378 10.34 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
5 embryo MP:0005380 10.31 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
6 hematopoietic system MP:0005397 10.29 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
7 immune system MP:0005387 10.26 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
8 mortality/aging MP:0010768 10.25 ARNT CITED2 EGLN1 EGLN3 EP300 EPAS1
9 muscle MP:0005369 10.22 EGLN1 EGLN2 EGLN3 EP300 EPAS1 HIF1A
10 craniofacial MP:0005382 10.2 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
11 liver/biliary system MP:0005370 10.11 ARNT EGLN1 EGLN2 EGLN3 EPAS1 HIF1A
12 nervous system MP:0003631 10.06 ARNT CITED2 EGLN1 EGLN3 EP300 EPAS1
13 normal MP:0002873 9.91 ARNT CITED2 EGLN3 EP300 HIF1A HIF1AN
14 neoplasm MP:0002006 9.85 ARNT EP300 HIF1A KMT2A TIGAR VHL
15 renal/urinary system MP:0005367 9.85 ARNT CITED2 EGLN1 EP300 HIF1A HIPK2
16 respiratory system MP:0005388 9.56 CITED2 EGLN1 EP300 EPAS1 HIF1A HIF1AN
17 vision/eye MP:0005391 9.23 CITED2 EGLN3 EP300 EPAS1 HIF1A HIPK2

Drugs & Therapeutics for Hypoxia

Drugs for Hypoxia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 729)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2
Zinc Approved, Investigational Phase 4 7440-66-6 32051
3
Bromhexine Approved Phase 4 3572-43-8
4
Cetirizine Approved Phase 4 83881-51-0 2678
5
Succinylcholine Approved Phase 4 306-40-1 5314
6
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
7
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
8
Ticagrelor Approved Phase 4 274693-27-5 9871419
9
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
10
Promethazine Approved, Investigational Phase 4 60-87-7 4927
11
Ipratropium Approved, Experimental Phase 4 22254-24-6, 60205-81-4 43232 657309
12
Terbutaline Approved Phase 4 23031-25-6 5403
13
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
14
Insulin glargine Approved Phase 4 160337-95-1
15
Insulin lispro Approved Phase 4 133107-64-9
16
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
17
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
18
Methazolamide Approved Phase 4 554-57-4 4100
19
Caffeine Approved Phase 4 58-08-2 2519
20
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
21
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
22
Bisoprolol Approved Phase 4 66722-44-9 2405
23
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
24
Bevacizumab Approved, Investigational Phase 4 216974-75-3
25
Adenosine Approved, Investigational Phase 4 58-61-7 60961
26
Dipyridamole Approved Phase 4 58-32-2 3108
27
Ibuprofen Approved Phase 4 15687-27-1 3672
28
Budesonide Approved Phase 4 51333-22-3 63006 5281004
29
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
30
Ranibizumab Approved Phase 4 347396-82-1 459903
31
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
32
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
33
Racepinephrine Approved Phase 4 329-65-7 838
34
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
35
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
36
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
37
Doxapram Approved, Vet_approved Phase 4 309-29-5 3156
38
Riociguat Approved Phase 4 625115-55-1
39
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
40
Acetaminophen Approved Phase 4 103-90-2 1983
41
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
42
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
43
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
44
Lopinavir Approved Phase 4 192725-17-0 92727
45
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
46
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
47
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
48
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
49
Benzydamine Approved Phase 4 642-72-8, 100-46-9 7504
50
Nifedipine Approved Phase 4 21829-25-4 4485

Interventional clinical trials:

(show top 50) (show all 2069)
# Name Status NCT ID Phase Drugs
1 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
2 Sevoflurane-based Volatile Induction and Maintenance of Anaesthesia (VIMA) Strategy Decreases the Risk of Postoperative Delirium in Elderly Patients With Registered Cerebral Hypoxemia Episodes During General Surgery Unknown status NCT02133638 Phase 4 Sevoflurane;Propofol
3 Comparison of Three Different Rates of Continuous Intravenous Sufentanil Infusion for Postoperative Pain Management Following Coblation Tonsillectomy or Adeno-tonsillectomy in Children Unknown status NCT02205580 Phase 4 continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion;continuous intravenous sufentanil 0.03μg•kg-1•h-1 infusion;continuous intravenous sufentanil 0.04μg•kg-1•h-1 infusion
4 Home Oxygen Therapy in the Ambulatory Treatment of Bronchiolitis Unknown status NCT01216553 Phase 4
5 Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia Unknown status NCT03192488 Phase 4 Cetirizine;Placebo oral capsule
6 Phase 3 Study of Postpartum Oxygen Inhalation for the Treatment of Postpartum Haemorrhage Unknown status NCT01180192 Phase 4 oxygen
7 Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation Unknown status NCT01595399 Phase 4 atropine;Placebo
8 Does the Early Use of Sodium Bicarbonate Improve Results of Cardiopulmonary Resuscitation Following Out-of-Hospital Cardiac Arrest - a Prospective, Controlled Clinical Trial Unknown status NCT01377337 Phase 4 sodium bicarbonate
9 Remifentanil for c-Section With General Anesthesia in Severe Preeclamptic Patients Unknown status NCT00567957 Phase 4 Remifentanil;Saline
10 Colloid Preload Versus Colloid Coload in Preventing Spinal Anesthesia-Induced Hypotension During Cesarean Section Deliveries: A Prospective, Randomized, Double-Blind Comparative Study Unknown status NCT02393196 Phase 4 hydroxyethyl starch (% 6 HES 130/0.4) (Voluven®);hydroxyethyl starch (%6 HES 130/0.4) (Voluven®)
11 Influence on Incidence of Postoperative Delirium by Various Sedatives in Elderly Patients With Hip Fracture Under Lumbar Anesthesia: A Randomized, Control and Multi-center Trial Unknown status NCT03346226 Phase 4 Dexmedetomidine Hydrochloride;Propofol
12 Use of Diphenhydramine as an Adjunctive Sedative for Colonoscopy in Patients Chronically on Opioids Unknown status NCT01967433 Phase 4 Diphenhydramine;Placebo
13 Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT Unknown status NCT02233790 Phase 4 Ticagrelor;Clopidogrel
14 Long-Term Oxygen Therapy (LTOT) in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure (CHF) Unknown status NCT00668408 Phase 4
15 Evaluation of High-dose Corticosteroids on Microcirculation Alterations in Cardiac Surgery, by FMD (Flow Mediated vasoDilation), Near Infrared Spectrophotometry (NIRS) and Biological Analysis (Syndecan-1) Unknown status NCT02798068 Phase 4 Solu-medrol or placebo administration
16 Continuous Positive Airway Pressure for Treatment of Postoperative Hypoxemia in Liver Transplant Unknown status NCT00510770 Phase 4
17 Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Unknown status NCT01116063 Phase 4 Inhaled iloprost
18 A Multicenter Study to Evaluate the Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency Unknown status NCT02594904 Phase 4 Yinzhihuang Oral Liquid
19 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
20 The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound Unknown status NCT00813631 Phase 4
21 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
22 Acute Ventilatory Response to Hypoxia During Sedation With Dexmedetomidine Compared to Propofol in Healthy Male Volunteers Completed NCT01873612 Phase 4
23 The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Hypoxia Completed NCT02760121 Phase 4 Acetazolamide;Methazolamide;Placebo
24 Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function Completed NCT00517725 Phase 4 carvedilol;bisoprolol;Nebivolol
25 5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females Completed NCT02356107 Phase 4 5-hydroxytryptophan and Creatine monohydrate
26 Effect of Systemic Hypoxia and Hyperoxia on Retinal Oxygen Saturation Completed NCT01692821 Phase 4 100% oxygen breathing;15% oxygen in N2 breathing;12% oxygen in N2 breathing
27 Apoptosis and Expression of Neovascularization-related Factors in Human Prostate Tissue After Administration of Dutasteride Completed NCT00880672 Phase 4 dutasteride
28 The Influence of Cerebral Blood Flow and Alkalosis on Neuromuscular Function During Environmental Stress Completed NCT01830335 Phase 4 Indomethacin;Placebo
29 The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Muscle Fatigue. Completed NCT02758470 Phase 4 Acetazolamide;Methazolamide
30 The Use of Statins for Myocardial Death Prevention: From Cell to Bedside Completed NCT00772564 Phase 4 Atorvastatin
31 Vasoactive Hormones During the Night in Patients With Obstructive Sleep Apnea Before and After Treatment With CPAP. Completed NCT00360659 Phase 4
32 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
33 Hyperoxia: An Unrecognized Mechanism for Inducing "Hypoxia-Like" Symptoms Completed NCT03268590 Phase 4 Oxygen
34 The Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy Completed NCT01725464 Phase 4
35 Continuous Positive Airway Pressure (CPAP) and Acetazolamide for Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00928655 Phase 4 acetazolamide;placebo
36 Can Muscle Dysfunction in COPD be Altered by Oxygenation in Patients With Intermittent Hypoxia on Exertion? Completed NCT01722370 Phase 4 Oxygen;Medical air equivalent
37 Acute Effect of Indacaterol Maleate on Static and Dynamic Lung Volume in COPD Subjects. Completed NCT01377051 Phase 4 Indacaterol maleate;Placebo
38 Preventive Effect of the PRetreatment With Intravenous Nicorandil on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndEergoing Coronary Angiography (PRINCIPLE Study): A Investigator-initiated, Control- Randomized, Phase IV Multicenter Study Completed NCT01103336 Phase 4 pretreatment with intravenous nicorandil vs. placebo before coronary angiography
39 Ketamine Effect on Recovery and Respiratory Outcomes After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study Completed NCT01997515 Phase 4 Ketamine;placebo
40 Comparison of the Cardiovascular, Metabolic and Respiratory Effects of Nebivolol and Carvedilol at High Altitude in Healthy Subjects. Completed NCT00924833 Phase 4 placebo;Carvedilol;Nebivolol
41 Effect Of Ketamine Infusion On Oxygenation And Ventilation Mechanics In Patients With Chronic Obstructive Pulmonary Disease Applied One Lung Ventilation Completed NCT02962999 Phase 4 Ketamine;Saline
42 Laryngoscope Versus CMAC for Endotracheal Intubation in Patients Undergoing Emergent Airway Management Completed NCT01710891 Phase 4
43 Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea Completed NCT02160223 Phase 4 Sugammadex;Neostigmine
44 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
45 Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage IV and V Completed NCT00563121 Phase 4
46 Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage V. Completed NCT00500396 Phase 4
47 Effect of Neuromuscular Blockade and Reversal by Sugammadex Versus Neostigmine on Breathing When Hypoxic or Hypercapnic in Volunteers Completed NCT02845375 Phase 4 Sugammadex;Neostigmine;Placebo
48 CPAP Effect on Nocturnal Evolution of Chemosensitivity Determinants in Sleep Apnea-hypopnea Patients With Isolated Nocturnal Hypertension or Day-nigh Sustained Hypertension Completed NCT02398032 Phase 4
49 Checklists and Upright Positioning in Endotracheal Intubation of Critically Ill Patients (Check-UP) Trial Completed NCT02497729 Phase 4
50 Doxapram as an Additive to Propofol Sedation in Sedation for Endoscopic Retrograde Cholangiopancreatography Completed NCT02171910 Phase 4 Doxapram;Placebo

Search NIH Clinical Center for Hypoxia

Genetic Tests for Hypoxia

Anatomical Context for Hypoxia

MalaCards organs/tissues related to Hypoxia:

40
Brain, Lung, Endothelial, Heart, Liver, Breast, Kidney

Publications for Hypoxia

Articles related to Hypoxia:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Prokineticin 2 relieves hypoxia/reoxygenation-induced injury through activation of Akt/mTOR pathway in H9c2 cardiomyocytes. 61
31899964 2020
2
Rosmarinic acid ameliorates hypoxia/ischemia induced cognitive deficits and promotes remyelination. 61
31719255 2020
3
SENP1-mediated NEMO de-SUMOylation inhibits intermittent hypoxia induced inflammatory response of microglia in vitro. 61
31549402 2020
4
Hypoxia modulates stem cell properties and induces EMT through N-glycosylation of EpCAM in breast cancer cells. 61
31584203 2020
5
Sirt6 attenuates hypoxia-induced tubular epithelial cell injury via targeting G2/M phase arrest. 61
31603249 2020
6
Appetite and energy intake responses to breakfast consumption and carbohydrate supplementation in hypoxia. 61
31870935 2020
7
Sex and age differentially affect GABAergic neurons in the mouse prefrontal cortex and hippocampus following chronic intermittent hypoxia. 61
31837319 2020
8
Hypoxia-ischemia in the immature rodent brain impairs serotonergic neuronal function in certain dorsal raphé nuclei. 61
31571657 2020
9
Identification of neuropeptides from eyestalk transcriptome profiling analysis of female oriental river prawn (Macrobrachium nipponense) under hypoxia and reoxygenation conditions. 61
31846692 2020
10
Bimetallic nanodots for tri-modal CT/MRI/PA imaging and hypoxia-resistant thermoradiotherapy in the NIR-II biological windows. 61
31864762 2020
11
Hypoxia upregulates Cxcl12 in hepatocytes by a complex mechanism involving hypoxia-inducible factors and transforming growth factor-β. 61
31951966 2020
12
Preventive preclinical efficacy of intravenously administered sphingosine-1-phosphate (S1P) in strengthening hypoxia adaptive responses to acute and sub-chronic hypobaric hypoxia. 61
31866409 2020
13
Knockdown of TUG 1 suppresses hypoxia-induced apoptosis of cardiomyocytes by up-regulating miR-133a. 61
31926162 2020
14
Suppression of long noncoding RNA NEAT1 attenuates hypoxia-induced cardiomyocytes injury by targeting miR-378a-3p. 61
31904498 2020
15
The HIF1αn gene and its association with hypoxia tolerance in the Asian seabass. 61
31935502 2020
16
Curcumin prophylaxis refurbishes alveolar epithelial barrier integrity and alveolar fluid clearance under hypoxia. 61
31778793 2020
17
Clemaichinenoside protects renal tubular epithelial cells from hypoxia/reoxygenation injury in vitro through activating the Nrf2/HO-1 signalling pathway. 61
31785117 2020
18
HOTAIRM1 lncRNA is downregulated in clear cell renal cell carcinoma and inhibits the hypoxia pathway. 61
31862408 2020
19
Intermittent hypoxia, energy expenditure, and visceral adipocyte recovery. 61
31628989 2020
20
AMPK activation increases postoperative cognitive impairment in intermittent hypoxia rats via direct activating PAK2. 61
31706798 2020
21
Long non-coding RNA Snhg3 protects against hypoxia/ischemia-induced neonatal brain injury. 61
31751562 2020
22
Normobaric oxygen treatment improves neuronal survival functional recovery and axonal plasticity after newborn hypoxia-ischemia. 61
31733311 2020
23
Hypoxia induces the activation of hepatic stellate cells through the PVT1-miR-152-ATG14 signaling pathway. 61
31893334 2020
24
Protective effects of irisin on hypoxia-reoxygenation injury in hyperglycemia-treated cardiomyocytes: Role of AMPK pathway and mitochondrial protection. 61
31268170 2020
25
Müller cells derived neurotrophin-3 inhibits hypoxia-induced photoreceptor apoptosis via the TrkC/ERK pathway. 61
31768729 2020
26
Upregulation of β3-adrenoceptors-a general marker of and protective mechanism against hypoxia? 61
31853614 2020
27
Hybrid Nanospheres to Overcome Hypoxia and Intrinsic Oxidative Resistance for Enhanced Photodynamic Therapy. 61
32023035 2020
28
Hypoxia-tropic nanozymes as oxygen generators for tumor-favoring theranostics. 61
31767443 2020
29
Biodegradable hypoxia biomimicry microspheres for bone tissue regeneration. 61
31648612 2020
30
Erratum to "Biodegradable hypoxia biomimicry microspheres for bone tissue regeneration". 61
31747839 2020
31
MicroRNA-1 facilitates hypoxia-induced injury by targeting NOTCH3. 61
32030815 2020
32
Acute intermittent hypercapnic hypoxia and sympathetic neurovascular transduction in men. 61
31805605 2020
33
Fetal cardiovascular response to acute hypoxia during maternal anesthesia. 61
32026576 2020
34
Medium conditioned by human mesenchymal stromal cells reverses low serum and hypoxia-induced inhibition of wound closure. 61
31761327 2020
35
PKCβ and reactive oxygen species mediate enhanced pulmonary vasoconstrictor reactivity following chronic hypoxia in neonatal rats. 61
31922892 2020
36
Advanced nanotechnology for hypoxia-associated antitumor therapy. 61
31965135 2020
37
The hypoxia-lactate axis tempers inflammation. 61
31819164 2020
38
Hypoxia Modulates Platelet Purinergic Signalling Pathways. 61
31858521 2020
39
Spotlighting the hypoxia-centrosome amplification axis. 61
32039498 2020
40
The repair and autophagy mechanisms of hypoxia-regulated bFGF-modified primary embryonic neural stem cells in spinal cord injury. 61
32027101 2020
41
The NuRD chromatin-remodeling complex enzyme CHD4 prevents hypoxia-induced endothelial Ripk3 transcription and murine embryonic vascular rupture. 61
31235857 2020
42
Exposure to Oil and Hypoxia Results in Alterations of Immune Transcriptional Patterns in Developing Sheepshead Minnows (Cyprinodon variegatus). 61
32015368 2020
43
Assessment of tumour hypoxia, proliferation and glucose metabolism in head and neck cancer before and during treatment. 61
31860336 2020
44
An innovative sequence of hypoxia-reoxygenation on adult mouse cardiomyocytes in suspension to perform multilabeling analysis by flow cytometry. 61
31875695 2020
45
Bclaf1 is a direct target of HIF-1 and critically regulates the stability of HIF-1α under hypoxia. 61
32029898 2020
46
Cellular oxygen sensing and the anesthesiologist: the Nobel-worthy discovery of hypoxia inducible factor and its implications in clinical practice. 61
31712964 2020
47
Effects of hypoxia on aerobic metabolism and active electrosensory acquisition in the African weakly electric fish Marcusenius victoriae. 61
31845335 2020
48
lncRNA ANRIL protects H9c2 cells against hypoxia-induced injury through targeting the miR-7-5p/SIRT1 axis. 61
31264206 2020
49
The effect of normoxia exposure on hypoxia tolerance and sensory sampling in a swamp-dwelling mormyrid fish. 61
31648062 2020
50
Expression of sirtuin type 3 in locus ceruleus is associated with long-term intermittent hypoxia-induced neurocognitive impairment in mice. 61
31876685 2020

Variations for Hypoxia

Expression for Hypoxia

Search GEO for disease gene expression data for Hypoxia.

Pathways for Hypoxia

Pathways related to Hypoxia according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.08 VHL PSMA7 MTOR HIF3A HIF1AN HIF1A
2 12.86 VHL MTOR HIF1A EPAS1 EP300 EGLN3
3
Show member pathways
12.62 VHL PDK1 MTOR HIF1A EPAS1 EP300
4 12.28 MTOR HIPK2 HIF1AN HIF1A EPAS1 EGLN1
5
Show member pathways
12.13 PSMA7 HIPK2 HIF1A EP300
6 11.85 VHL PDK1 MTOR HIF1A EP300 EGLN3
7 11.84 MTOR HIF1A EP300
8 11.84 HIF1AN HIF1A EP300 EGLN1 ARNT
9
Show member pathways
11.8 VHL HIF1A EPAS1 ARNT
10 11.72 HIF1A EP300 EGLN3 EGLN1 CITED2 ARNT
11 11.66 TIGAR PDK1 MTOR HIF1A
12
Show member pathways
11.59 HIF1A EP300 ARNT
13 11.4 HIF1A EP300 ARNT
14 11.38 HIF1AN HIF1A EGLN1 ARNT
15
Show member pathways
11.36 HIF1AN HIF1A EPAS1 EP300 EGLN3 CITED2
16 11.29 VHL PSMA7 HIF1AN HIF1A EP300 EGLN2
17 10.98 VHL HIF3A HIF1AN HIF1A ARNT
18 10.81 VHL EPAS1
19 10.81 VHL HIF1AN EPAS1 EP300 EGLN3 EGLN2
20 10.53 HIF1AN HIF1A

GO Terms for Hypoxia

Cellular components related to Hypoxia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.97 VHL TIGAR PSMA7 MTOR KMT2A HILPDA
2 nucleus GO:0005634 9.89 VHL TIGAR PSMA7 PDK1 MTOR KMT2A
3 transcription factor complex GO:0005667 9.56 HIF1A EPAS1 EP300 ARNT
4 nucleoplasm GO:0005654 9.53 VHL PSMA7 PDK1 MTOR KMT2A HIPK2
5 RNA polymerase II transcription factor complex GO:0090575 9.5 HIPK2 HIF1A ARNT

Biological processes related to Hypoxia according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 10.15 VHL KMT2A HIF3A HIF1A EPAS1 EP300
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.06 KMT2A HIPK2 HIF3A HIF1A EPAS1 EP300
3 apoptotic process GO:0006915 10.01 TIGAR KMT2A HIPK2 HIF3A EP300 EGLN3
4 positive regulation of transcription, DNA-templated GO:0045893 9.98 VHL KMT2A HIPK2 HIF1A EP300 CITED2
5 post-translational protein modification GO:0043687 9.91 VHL PSMA7 HIF3A HIF1A EPAS1
6 transcription by RNA polymerase II GO:0006366 9.9 KMT2A HIF3A HIF1A EPAS1
7 positive regulation of endothelial cell proliferation GO:0001938 9.76 MTOR HIF1A ARNT
8 cellular response to hypoxia GO:0071456 9.7 TIGAR MTOR HYOU1 HIPK2 HILPDA HIF1A
9 positive regulation of transforming growth factor beta receptor signaling pathway GO:0030511 9.65 HIPK2 EP300 CITED2
10 mRNA transcription by RNA polymerase II GO:0042789 9.62 HIF1A ARNT
11 embryonic placenta development GO:0001892 9.62 HIF1A EPAS1 CITED2 ARNT
12 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.61 HIF1A ARNT
13 embryonic hemopoiesis GO:0035162 9.61 KMT2A HIF1A
14 response to hypoxia GO:0001666 9.61 HIF3A HIF1A EPAS1 EP300 EGLN3 EGLN2
15 embryonic camera-type eye morphogenesis GO:0048596 9.59 HIPK2 CITED2
16 iris morphogenesis GO:0061072 9.58 HIPK2 HIF1A
17 regulation of transcription from RNA polymerase II promoter in response to oxidative stress GO:0043619 9.58 HIF1A EPAS1 ARNT
18 voluntary musculoskeletal movement GO:0050882 9.57 MTOR HIPK2
19 oxygen homeostasis GO:0032364 9.56 HIF1A EGLN1
20 peptidyl-proline hydroxylation to 4-hydroxy-L-proline GO:0018401 9.56 P4HTM EGLN3 EGLN2 EGLN1
21 negative regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061428 9.54 VHL HIF1AN CITED2
22 hypoxia-inducible factor-1alpha signaling pathway GO:0097411 9.52 PDK1 HIF1A
23 positive regulation of hormone biosynthetic process GO:0046886 9.49 HIF1A ARNT
24 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.36 VHL PSMA7 HIF3A HIF1AN HIF1A EPAS1

Molecular functions related to Hypoxia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.38 VHL TIGAR PSMA7 PDK1 MTOR KMT2A
2 DNA-binding transcription factor activity GO:0003700 10 KMT2A HIF3A HIF1A EPAS1 CITED2 ARNT
3 oxidoreductase activity GO:0016491 9.95 P4HTM HIF1AN EGLN3 EGLN2 EGLN1
4 transcription factor binding GO:0008134 9.88 VHL HIF1A EPAS1 EP300 ARNT
5 transcription coactivator activity GO:0003713 9.84 HIPK2 EP300 CITED2 ARNT
6 protein dimerization activity GO:0046983 9.81 HIF3A HIF1A EPAS1 ARNT
7 iron ion binding GO:0005506 9.72 P4HTM HIF1AN EGLN3 EGLN2 EGLN1
8 RNA polymerase II activating transcription factor binding GO:0001102 9.67 HIPK2 EP300 CITED2
9 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.67 P4HTM EGLN3 EGLN2 EGLN1
10 dioxygenase activity GO:0051213 9.65 P4HTM HIF1AN EGLN3 EGLN2 EGLN1
11 histone acetyltransferase binding GO:0035035 9.61 HIF1A EPAS1 CITED2
12 oxygen sensor activity GO:0019826 9.46 HIF1AN EGLN2
13 L-ascorbic acid binding GO:0031418 9.46 P4HTM EGLN3 EGLN2 EGLN1
14 peptidyl-proline 4-dioxygenase activity GO:0031545 9.13 EGLN3 EGLN2 EGLN1
15 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors GO:0016706 9.02 P4HTM HIF1AN EGLN3 EGLN2 EGLN1

Sources for Hypoxia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
73